ImmunityBio Inc (NASDAQ:IBRX) price on Wednesday, April 30, rose 0.80% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.51.
A look at the stock’s price movement, the close in the last trading session was $2.49, moving within a range at $2.4101 and $2.51. The beta value (5-Year monthly) was -0.127. Turning to its 52-week performance, $10.01 and $2.28 were the 52-week high and 52-week low respectively. Overall, IBRX moved -16.61% over the past month.
ImmunityBio Inc’s market cap currently stands at around $2.21 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-02.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IBRX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 0 recommend IBRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Sell which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IBRX’s current price about -5.50% and -12.57% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.10, while 7-day volatility ratio is 5.29% and 9.31% in the 30-day chart. Further, ImmunityBio Inc (IBRX) has a beta value of 0.20, and an average true range (ATR) of 0.23. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -139.04% off current price level while to achieve the yearly target high, price needs to move -139.04%. Nonetheless, investors will most likely welcome a -139.04% jump to $6 which is the analysts’ median price.
If we refocus on ImmunityBio Inc (NASDAQ:IBRX), historical trading data shows that trading volumes averaged 4.78 over the past 10 days and 6.19 million over the past 3 months. The company’s latest data on shares outstanding shows there are 852.74 million shares.
The 89.60% of ImmunityBio Inc’s shares are in the hands of company insiders while institutional holders own 9.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 67.18 million on 2025-04-15, giving us a short ratio of 9.06. The data shows that as of 2025-04-15 short interest in ImmunityBio Inc (IBRX) stood at 1935.0000000000002 of shares outstanding, with shares short rising to 59.54 million registered in 2025-03-14. Current price change has pushed the stock -1.95% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IBRX stock continues to rise going into the next quarter.
